Zhiyun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhiyun Wang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Dan Wu
Department of Pharmacy, Children's Hospital of Fudan University , Shanghai , China
1 shared publication - Xuan Gao
Children’s Hospital, Fudan University, 399 Wanyuan Road, Shanghai 201102, China
1 shared publication - Yi Wang
Department of Neurology, Children’s Hospital of Fudan University, National Children’s Medical Center
1 shared publication - Zhiping Li
Department of Pharmacy, Children's Hospital of Fudan University , Shanghai , China
1 shared publication
Latest Publications
- Open Access
- 26 March 2014
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 2, 17
Current Status of Pediatric Labeling in China and the near Future Efforts Needed for the Country
Background: Children are recognized as “therapeutic orphan” in many parts of the world, one expression of this is the lack of adequate pediatric labeling information. Some researches have been done to investigate the pediatric labeling condition in the U.S. and other countries, but no national studies had been carried out in China. This survey was conducted aiming to inquire the current situation of pediatric labeling in China.Methods: We investigated 6020 child-applied medicines from 15 representative Chinese hospitals, and analyzed the information according to the dosage forms, therapeutic category, and label information integrity.Results: Among all these medicines, only 238 (3.95%) are pediatric products, the rest are adult formulations with an extended use in children. The major pediatric formulations were injection (45.95%), tablet (23.69%) and capsule (4.93%), respectively. Alimentary tract/ metabolism medicine (24.70%) and infections medicines (20.60%) had the most species . In prescription drugs, only 210 of 5187 (4%) medicines had adequate pediatric labeling information. The main cause of this deficiency was lack of evidence derived from pediatric clinical trials. Conclusion: The dilemma of “therapeutic orphan” requires significant attention. Inadequate labeling information and lack of pediatric clinical trials were two prominent issues in China. It calls for more efforts from pharmaceutical industries, regulatory agencies, and legislature in China to collaborate and find solution to improve the situation.
- 26 March 2014
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 2, 17
Open AccessCurrent Status of Pediatric Labeling in China and the near Future Efforts Needed for the Country
Background: Children are recognized as “therapeutic orphan” in many parts of the world, one expression of this is the lack of adequate pediatric labeling information. Some researches have been done to investigate the pediatric labeling condition in the U.S. and other countries, but no national studies had been carried out in China. This survey was conducted aiming to inquire the current situation of pediatric labeling in China.Methods: We investigated 6020 child-applied medicines from 15 representative Chinese hospitals, and analyzed the information according to the dosage forms, therapeutic category, and label information integrity.Results: Among all these medicines, only 238 (3.95%) are pediatric products, the rest are adult formulations with an extended use in children. The major pediatric formulations were injection (45.95%), tablet (23.69%) and capsule (4.93%), respectively. Alimentary tract/ metabolism medicine (24.70%) and infections medicines (20.60%) had the most species . In prescription drugs, only 210 of 5187 (4%) medicines had adequate pediatric labeling information. The main cause of this deficiency was lack of evidence derived from pediatric clinical trials. Conclusion: The dilemma of “therapeutic orphan” requires significant attention. Inadequate labeling information and lack of pediatric clinical trials were two prominent issues in China. It calls for more efforts from pharmaceutical industries, regulatory agencies, and legislature in China to collaborate and find solution to improve the situation.